{"id":463,"date":"2022-01-25T10:42:00","date_gmt":"2022-01-25T18:42:00","guid":{"rendered":"https:\/\/www.adarx.com\/?p=463"},"modified":"2024-12-12T10:43:30","modified_gmt":"2024-12-12T18:43:30","slug":"adarx-pharmaceuticals-expands-leadership-team","status":"publish","type":"post","link":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/","title":{"rendered":"ADARx Pharmaceuticals Expands Leadership Team"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>San Diego, California, January 25, 2022 \u2013&nbsp;<\/strong><a href=\"https:\/\/www.adarx.com\/dev\/\">ADARx Pharmaceuticals, Inc.<\/a>, a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cI am excited to welcome Chris to the ADARx team at this important time in our company,\u201d said Dr. Zhen Li, President and Chief Executive officer of ADARx. \u201cChris\u2019 manufacturing expertise will prove to be an invaluable asset as we move the company into clinical development and beyond.\u201d&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Claeboe\u2019s role at ADARx will focus on developing our RNA therapeutics, establishing a manufacturing network, leading drug substance and drug product production, and oversight of CMC regulatory. Dr. Claeboe brings to ADARx extensive experience in CGMP drug substance and drug product manufacturing through various stages of clinical development to commercialization. He was most recently Executive Director at ChemoCentryx, Inc., in which he contributed significantly to the CMC development activities for their recently approved drug Tavneos\u2122. Prior positions include Director at Codexis, Inc. Dr. Claeboe received a Ph.D. in Organic Chemistry from the University of Virginia. He then completed his Postdoctoral Fellowship at Indiana University. Dr. Claeboe also earned his MBA from Indiana University\u2019s Kelley School of Business.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About ADARx<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Contact ADARx<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Roselle Corbaley<br>(877) 232-7974<br><a href=\"mailto:ir@adarx.com\">ir@adarx.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>San Diego, California, January 25, 2022 \u2013&nbsp;ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.&nbsp; \u201cI am excited to welcome Chris to the ADARx team at this important time in our company,\u201d said [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-463","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADARx Pharmaceuticals Expands Leadership Team - ADARx Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADARx Pharmaceuticals Expands Leadership Team - ADARx Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"San Diego, California, January 25, 2022 \u2013&nbsp;ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.&nbsp; \u201cI am excited to welcome Chris to the ADARx team at this important time in our company,\u201d said [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/\" \/>\n<meta property=\"og:site_name\" content=\"ADARx Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-25T18:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-12T18:43:30+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\"},\"headline\":\"ADARx Pharmaceuticals Expands Leadership Team\",\"datePublished\":\"2022-01-25T18:42:00+00:00\",\"dateModified\":\"2024-12-12T18:43:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/\"},\"wordCount\":291,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/\",\"name\":\"ADARx Pharmaceuticals Expands Leadership Team - ADARx Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\"},\"datePublished\":\"2022-01-25T18:42:00+00:00\",\"dateModified\":\"2024-12-12T18:43:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADARx Pharmaceuticals Expands Leadership Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"ADARx Pharmaceuticals\",\"description\":\"Providing hope for patients with intractable disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.adarx.com\\\/dev\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADARx Pharmaceuticals Expands Leadership Team - ADARx Pharmaceuticals","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"ADARx Pharmaceuticals Expands Leadership Team - ADARx Pharmaceuticals","og_description":"San Diego, California, January 25, 2022 \u2013&nbsp;ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing.&nbsp; \u201cI am excited to welcome Chris to the ADARx team at this important time in our company,\u201d said [&hellip;]","og_url":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/","og_site_name":"ADARx Pharmaceuticals","article_published_time":"2022-01-25T18:42:00+00:00","article_modified_time":"2024-12-12T18:43:30+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/#article","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/"},"author":{"name":"admin","@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031"},"headline":"ADARx Pharmaceuticals Expands Leadership Team","datePublished":"2022-01-25T18:42:00+00:00","dateModified":"2024-12-12T18:43:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/"},"wordCount":291,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/","url":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/","name":"ADARx Pharmaceuticals Expands Leadership Team - ADARx Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/#website"},"datePublished":"2022-01-25T18:42:00+00:00","dateModified":"2024-12-12T18:43:30+00:00","author":{"@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031"},"breadcrumb":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.adarx.com\/dev\/"},{"@type":"ListItem","position":2,"name":"ADARx Pharmaceuticals Expands Leadership Team"}]},{"@type":"WebSite","@id":"https:\/\/www.adarx.com\/dev\/#website","url":"https:\/\/www.adarx.com\/dev\/","name":"ADARx Pharmaceuticals","description":"Providing hope for patients with intractable disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adarx.com\/dev\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.adarx.com\/dev"]}]}},"_links":{"self":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/comments?post=463"}],"version-history":[{"count":1,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/463\/revisions"}],"predecessor-version":[{"id":464,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/463\/revisions\/464"}],"wp:attachment":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media?parent=463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/categories?post=463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/tags?post=463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}